Pharmaceuticals · TSE: 4519
Chugai Pharmaceutical earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 23 Jul 2027
Latest: Q3 2026
Chugai filed the Hemlibra autoinjector for a 2027 launch and showed divarasib beating first-generation KRAS G12C inhibitors head-to-head, while Lunsumio and Elevidys widened domestic growth.
Chugai pushed several products forward this quarter. The Hemlibra autoinjector was filed in Japan for a 2027 launch in Japan and globally, and Enspryng won US approval for thyroid eye disease. In Japan, the new products Lunsumio and Elevidys (launched February 2026) kept growing. Exports of NEMLUVIO to Galderma and Alecensa to Roche also rose. Domestic shipments were pulled forward ahead of an ERP switch, a one-time boost in the low-JPY30 billion range.
Quarters
KPI history